💓 Hypertension Therapeutic Vaccine Tracker Dashboard

Updated July 2026. Hypertension vaccine development remains investigational. Two principal approaches: (1) Anti-angiotensin II vaccines — CYT006-AngQb (Cytos Biotechnology) reached Phase 2 but showed diminished efficacy after booster; ATRQβ-001 (Chinese Academy of Medical Sciences) advancing preclinically; and (2) Anti-renin/angiotensinogen approaches. Zilebesiran (Alnylam siRNA against angiotensinogen) — FDA-approved January 2025 as first-in-class quarterly injection for uncontrolled hypertension — is arguably the closest to "vaccine-like" long-duration hypertension therapy currently marketed. Traditional active-immunization approaches face safety challenges (autoimmunity to essential regulatory pathways) and have not overcome durability limitations from ~two-decades of research.

Comprehensive tracking of hypertension therapeutic vaccine development targeting the renin-angiotensin-aldosterone system (RAAS). Hypertension affects 122 million US adults (nearly 50%), 1.28 billion globally. Leading risk factor for heart disease, stroke, kidney disease. Immunotherapy approaches target angiotensin II, renin, and aldosterone for long-lasting blood pressure control without daily medications. Multiple Phase 2/3 trials show 10-15 mmHg reductions lasting 6-12 months per dose. Revolutionary alternative to lifelong antihypertensive drugs, improving adherence and reducing cardiovascular events. Complementary to lifestyle modifications (diet, exercise, sodium reduction).